Skip to main content
SpringerLink
Log in

Development of New Therapeutical Agents for Treatment of Insomnia and Other Sleeps Disorders

  • Chapter
  • First Online:
Drug Treatment of Sleep Disorders

Part of the book series: Milestones in Drug Therapy ((MDT))

  • 1990 Accesses

Abstract

The development of a new therapeutic agent for human use is a complex, highly regulated, risky, and expensive process which, in the case of insomnia and other sleep disorders, presents some special challenges typical of this group of diseases. The development of a new therapeutic agent consists of a series of Nonclinical and clinical phases in which the new drug candidate has to demonstrate, among other things, a favorable benefit/risk ratio in the treatment of a given disease before receiving market authorization and be used to treat patients. In the Nonclinical development phase chemical development, formulation development, analytical methods development, pharmacology development, pharmacokinetic development, and Nonclinical safety evaluation of the new drug candidate are carried out. The main goal of these studies, conducted both in vitro and in vivo in laboratory animals, is to collect sufficient information to authorize the evaluation of the new therapeutic agent in humans. The clinical development phase of a new therapeutic agent consists of several steps in which the new drug candidate is administered to humans in a stepwise progression starting with administration to a reduced number of healthy volunteers and then progressing to patients in order to assess its safety and efficacy. In addition, in the case of hypnotics, specific points of concerns such as development of tolerance, potential for drug abuse, interaction with other drugs, and next-day performance should also be addressed and evaluated promptly and properly. Several guidelines issued by regulatory agencies are available to guide investigators throughout the entire development process and should be consulted to correctly design and execute the individual studies of the development plan. Nevertheless, during the development of new therapeutic agents for insomnia and other sleep disorders, specific issues can arise which are not covered by the available guidelines. Therefore, it is always highly advisable to consult with regulatory agencies on how to address these specific points. A better understanding on the drug regulatory framework and rules can maximize the chances of a successful development of a new therapeutic agent for treatment of insomnia and other sleep disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    After this book went to press, on Aug 13th 2014, the US Food and Druf Administration approved Suvorexant (Belsomra) tablets to treat difficulty in falling and stying alseep (insomnia). Suvorexant is the first approved drug of the orexin antagonists class.

References

  • Bain KT (2006) Management of chronic insomnia in elderly persons. Am J Geriatr Pharmacother 4:168–192

    Article  CAS  PubMed  Google Scholar 

  • Bateson AN (2002) Basic pharmacologic mechanism involved in benzodiazepine tolerance and withdrawal. Curr Pharm Des 1:5–21

    Article  Google Scholar 

  • Bodrogi J, Kaló Z (2010) Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. Br J Pharmacol 159:1367–1373

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Cardario B et al (2011) Drugs and the risk of falling. Guidance document. http://www.health.gov.bc.ca/prevention/pdf/medications-and-the-risk-of-falling.pdf

  • Chalkidou K (2009) Comparative effectiveness review within the U.K.’s National Institute for Health and Clinical Excellence. The Commonwealth fund 59: pub 1296

    Google Scholar 

  • Clare G (2012) The in-vitro mammalian chromosomal aberration test. Methods Mol Biol 817:69–91

    Article  CAS  PubMed  Google Scholar 

  • Costantino HR, Illum L, Brandt G et al (2007) Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 337:1–24

    Article  CAS  PubMed  Google Scholar 

  • De la Herrán-Arita AK, Druken-Colin R (2012) Models for narcolepsy with catalepsy drug discovery. Expert Opin Drug Discov 7:152–164

    Google Scholar 

  • de Lecea L, Huerta R (2014) Hypocretin (orexin) regulation of sleep-to-wake transition. Front Pharmacol 5:16

    Article  PubMed Central  PubMed  Google Scholar 

  • de Lecea L, Kilduff TS, Peyron C et al (1998) The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 95:322–327

    Article  PubMed Central  PubMed  Google Scholar 

  • Deacon RM (2013) Measuring the strength of mice. J Vis Exp 76:2610

    Google Scholar 

  • DiMasi JA, Feldman J, Seckler A et al (2010) Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 87:272–277

    Article  CAS  PubMed  Google Scholar 

  • Doering S, Boeckmann JA, Hugger S et al (2008) Ambulatory polysomnography for the assessment of sleep bruxism. J Oral Rahabil 35:572–576

    Article  CAS  Google Scholar 

  • Equihua AC, De la Herrán-Arita AK, Drucker-Colin R (2013) Orexin receptor antagonists as therapeutic agents for insomnia. Front Pharmacol 4:1–10

    Article  Google Scholar 

  • European Medicines Agency (EMA) (1994) Pharmacokinetics and metabolic studies in the safety evaluation of new medicinal products in animals. 3BS 11A

    Google Scholar 

  • European Medicines Agency (EMA) (2001) Safety pharmacology studies for human pharmaceuticals. CPMP/ICH/539/00

    Google Scholar 

  • European Medicines Agency (EMA) (2006) Guideline on the non-clinical investigation of the dependence potential of medicinal products. EMEA/CHMP/SWP/94227/2004

    Google Scholar 

  • European Medicines Agency (EMA) (2007) Guideline on strategy to identify and mitigate risks for first in human clinical trials with investigational medicinal products. EMEA/CHMP/SWP/28367/07

    Google Scholar 

  • European Medicinal Agency (EMA) (2008) Guidelines on risk assessment of medicinal products on human reproduction and lactation: from data to labelling. EMEA/CHMP/203927/2005

    Google Scholar 

  • European Medicines Agency (EMA) (2010a) Guideline on repeated dose toxicity. CPMP/SWP/1042/99 Rev 1 Corr

    Google Scholar 

  • European Medicines Agency (EMA) (2010b) Reflection paper on non-clinical evaluation of drug-induced liver injury (DILI). EMEA/CHMP/SWP/150115/2006

    Google Scholar 

  • European Medicines Agency (EMA) (2011) Medicinal products for the treatment of insomnia. CHMP/16274/2009 Rev 1

    Google Scholar 

  • European Medicines Agency (EMA) (2014) Guideline on medicinal products for the treatment of insomnia. EMA/213031/2014

    Google Scholar 

  • Food and Drug Administration (1977) Guideline for the clinical evaluation of hypnotic drugs

    Google Scholar 

  • Food and Drug Administration (2002) Guidance for industry immunotoxicology evaluation of investigational new drugs

    Google Scholar 

  • Food and Drug Administration (2005a) Good pharmacovigilance practices and pharmacoepidemiologic assessment

    Google Scholar 

  • Food and Drug Administration (2005b) Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers

    Google Scholar 

  • Food and Drug Administration (2006) Exploratory IND studies

    Google Scholar 

  • Food and Drug Administration (2008) Safety testing of drug metabolites

    Google Scholar 

  • Food and Drug Administration (2010) Assessment of abuse potential of drugs

    Google Scholar 

  • Food and Drug Administration (2011) Reproductive and developmental toxicities–integrating study results to assess concern

    Google Scholar 

  • Food and Drug Administration (2013) FDA-approved drugs to treat sleep disorders. J Psychosoc Nurs Ment Health Serv 51:9–10

    Google Scholar 

  • Greenblatt DJ, Roth T (2012) Zolpidem for insomnia. Expert Opin Pharmacother 13:879–893

    Article  CAS  PubMed  Google Scholar 

  • Griffiths RR, Johnson NW (2005) Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 66(S9):31–41

    CAS  PubMed  Google Scholar 

  • Gunja N (2013) In the Zzz zone: the effects of Z-drugs on human performance and driving. J Med Toxicol 9:163–171

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hajak G, Müller WE, Wittchen HU et al (2003) Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 98:1371–1378

    Article  CAS  PubMed  Google Scholar 

  • Heit HA (2003) Addiction, physical dependence, and tolerance: precise definition to help clinicians evaluate and treat chronic patients. J Pain Palliat Care Pharmacother 17:15–29

    PubMed  Google Scholar 

  • Hesse LM, von Moltke LL, Greenblatt DJ (2003) Clinically important drug interaction with zopiclone, zolpidem and zaleplon. CNS Drugs 17:513–532

    Article  CAS  PubMed  Google Scholar 

  • ICH Harmonised Tripartite Guideline (1994a) Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies. Guideline S3A

    Google Scholar 

  • ICH Harmonised Tripartite Guideline (1994b) Guidance for repeated dose tissue distribution studies. Guideline S3B

    Google Scholar 

  • ICH Harmonised Tripartite Guideline (1995) Guideline on the need for carcinogenicity studies of pharmaceuticals. Guideline S1A

    Google Scholar 

  • ICH Harmonised Tripartite Guideline (1996) Stability for new dosage forms. Guideline Q1C

    Google Scholar 

  • ICH Harmonised Tripartite Guideline (1998) Duration of chronic testing in animals (rodent and non rodent toxicity testing). Guideline S4

    Google Scholar 

  • ICH Harmonised Tripartite Guideline (2005a) Detection of toxicity to reproduction for medicinal products and toxicity to male fertility. Guideline S5(R2)

    Google Scholar 

  • ICH Harmonised Tripartite Guideline (2005b) Immunotoxicity studies for human pharmaceuticals. Guideline S8

    Google Scholar 

  • ICH Harmonised Tripartite Guideline (2000) Safety pharmacology studies for human pharmaceuticals. Guideline S7A

    Google Scholar 

  • ICH Harmonised Tripartite Guideline (2009) Guideline on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Guideline M3(R2)

    Google Scholar 

  • ICH Harmonised Tripartite Guideline (2011) Guideline on genotoxicity testing and data interpretation for pharmaceuticals intended for human use. Guideline S2(R1)

    Google Scholar 

  • ICH Harmonised Tripartite Guideline (2012) Development and manufacture of drug substance (chemical entities and biotechnological/biological entities). Guideline Q11

    Google Scholar 

  • Ilomäki J, Paljärvi T, Korhonen MJ et al (2013) Prevalence of concomitant use of alcohol and sedative-hypnotic drugs in middle and older aged persons: a systematic review. Ann Pharmacother 47:257–268

    Article  PubMed  Google Scholar 

  • International Society for Pharmacoeconomics and Outcome Research. Pharmacoeconomic guidelines around the world. www.ispor.org/peguidelines/index.asp

  • Johannesen L, Vicente J, Gray RA et al (2014) Improving the assessment of heart toxicity for all new drugs through translational regulatory science. Clin Pharmacol Ther 95:501–508

    Article  CAS  PubMed  Google Scholar 

  • Kamel NS, Gammack JK (2006) Insomnia in the elderly: cause, approach, and management. Am J Med 119:463–469

    Article  PubMed  Google Scholar 

  • Kanbayashi T, Inoue Y, Chiba S et al (2002) CSF hypocretin-1 (orexin A) concentrations in narcolepsy with and without catalepsy and idiopathic hipersomnia. J Sleep Res 11:91–93

    Article  PubMed  Google Scholar 

  • Katchman AN, Koerner J, Tosaka T et al (2005) Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and non torsadogenic drugs. J Pharmacol Exp Ther 316:1098–1106

    Article  PubMed  Google Scholar 

  • Kolla BP, Lovely JK, Mansukhani MP et al (2013) Zolpidem is independently associated with increased risk of inpatient falls. J Hosp Med 8:1–6

    Article  PubMed  Google Scholar 

  • Kryger MH, Roth T, Dement WC (eds) (2011) Principles and practice of sleep medicine, 5th edn. Elsevier Saunders, St. Louis, MO

    Google Scholar 

  • Krystal AD, Benca RM, Kilduff TS (2013) Understanding the sleep-wake cycle: sleep, insomnia and the orexin system. J Clin Psychiatry S1:3–20

    Article  Google Scholar 

  • López-Muñoz F, Ucha-Udabe R, Alamo C (2005) The history of barbiturates a century after their clinical introduction. Neuropsychiatr Dis Treat 1:329–343

    PubMed Central  PubMed  Google Scholar 

  • Martelmans K, Zeiger E (2000) The Ames salmonella/microsome mutagenicity assay. Mutat Res 455:29–60

    Article  Google Scholar 

  • Mets MA, Volkerts ER, Oliver B (2010) Effect of hypnotic drugs on body balance and standing steadiness. Sleep Med Rev 14:259–267

    Article  PubMed  Google Scholar 

  • Meyer OA, Tilson HA, Byrd WC (1979) A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav Toxicol 1:233–236

    CAS  PubMed  Google Scholar 

  • Mignot E, Lammers GJ, Ripley B et al (2002) The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 59:1553–1562

    Article  PubMed  Google Scholar 

  • Milić M, Divljaković J, Rapalli S et al (2012) The role of α1 and α5 subunits containing GABAA receptors in motor impairment induced by benzodiazepine in rats. Behav Pharmacol 23:191–197

    Article  PubMed Central  PubMed  Google Scholar 

  • Mould R, Brown J, Marshall FH et al (2014) Binding kinetics differentiates functional antagonism of orexin-2 receptor ligands. Br J Pharmacol 171:351–363

    Article  CAS  PubMed  Google Scholar 

  • Nakamura M, Kanbayashi T, Sugiura T et al (2010) Relationship between clinical characteristics of narcolepsy and CSF orexin-A levels. J Sleep res 20:45–49

    Article  Google Scholar 

  • Nishino S, Ripley B, Overeem S et al (2000) Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355:39–40

    Article  CAS  PubMed  Google Scholar 

  • Noble RE (2003) Drug therapy in the elderly. Metabolism 52(S2):27–30

    Article  CAS  PubMed  Google Scholar 

  • Nordmann H (1985) Grip strength test and infrared thermometry as non-invasive methods to complement acute toxicity data in mice. Arch Toxicol Suppl 8:435–441

    Article  CAS  PubMed  Google Scholar 

  • Nutt DJ, Sathl SM (2010) Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol 24:1601–1612

    Article  CAS  PubMed  Google Scholar 

  • O’brien CP (2005) Benzodiazepines use, abuse and dependence. J Clin Psychiatry 2:28–33

    Google Scholar 

  • Obayashi K, Araki T, Nakamura K et al (2013) Risk of falling and hypnotic drugs: retrospective drugs of inpatients. Drugs R D 13:159–164

    Article  PubMed Central  PubMed  Google Scholar 

  • OECD (1997) In-vitro mammalian chromosomal Aberration test. Test No: 473

    Google Scholar 

  • Owen RT (2009) Novel zolpidem formulations. Drugs Today 45:395–400

    Article  CAS  PubMed  Google Scholar 

  • Owens JA (2006) Pediatric insomnia. Sleep Med Clin 1:423–435

    Article  Google Scholar 

  • Rabbani M, Wright EJ, Little HJ (1995) Tolerance of competitive NMDA antagonists, but not cross tolerance with barbiturates. Pharmacol Biochem Behav 50:9–15

    Article  CAS  PubMed  Google Scholar 

  • Rowlett JK, Platt DM, Lelas S et al (2005) Different GABAA receptor subtypes mediate the anxiolytic, abuse-related and motor effects of benzodiazepine-like drugs in primates. Proc Natl Acad Sci USA 102:915–920

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Sakurai T, Amemiya A, Ishii M et al (1998) Orexin and orexin receptors: a family of hypothalamic neuropeptides and G-protein coupled receptors that regulate feeding and feeding behavior. Cell 4:573–585

    Article  Google Scholar 

  • Saunders JB (1986) Drugs and alcohol—their interactions and how to avoid them. Curr Ther 27:31–53

    Google Scholar 

  • Sellayah D, Sikder D (2013) Food for thought: understanding the multifaceted nature of orexins. Endocrinology 154:2990–3999

    Article  Google Scholar 

  • Stephenson T (2005) How children’s responses to drugs differ from adults. Br J Clin Pharmacol 59:670–673

    Article  PubMed Central  PubMed  Google Scholar 

  • Toth LA, Bhargava P (2013) Animal models of sleep disorders. Comp Med 63:91–104

    CAS  PubMed Central  PubMed  Google Scholar 

  • Uzun S, Kozumplik O, Jakovljevic M et al (2010) Side effects of treatment with benzodiazepines. Psychiatr Danub 22:90–93

    PubMed  Google Scholar 

  • Vinkers CH, Oliver B (2012) Mechanism underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABAA receptor modulators? Adv Pharmacol Sci 2012:416864

    PubMed Central  PubMed  Google Scholar 

  • Wang D, Wong KK, Dungan GC et al (2008) The validity of wrist actimetry assessment of sleep with and without sleep apnea. J Clin Sleep Med 4:450–455

    PubMed Central  PubMed  Google Scholar 

  • Wick JY (2013) The history of benzodiazepines. Consult Pharm 28:538–548

    Article  PubMed  Google Scholar 

  • Winrow CJ, Renger JJ (2014) Discovery and development of orexin receptor antagonists as therapeutic for insomnia. Br J Pharmacol 17:283–293

    Article  Google Scholar 

  • Zisapel N (2012) Drugs for insomnia. Expert Opin Emerg Drugs 17:299–317

    Article  CAS  PubMed  Google Scholar 

  • Zosel A, Osterberg EC, Mycyk MB (2011) Zolpidem miuse with other medications or alcohol frequently results in intensive cure unit admission. Am J Ther 18:305–208

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Grupo Ferrer Internacional, Joan Buscallá 1, 08173, Sant Cugat del Valles, Barcelona, Spain

    Gloria Martin

  2. Independent Pharmaceutical Consultant, Barcelona, Spain

    Antonio Guglietta

Authors
  1. Gloria Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonio Guglietta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gloria Martin .

Editor information

Editors and Affiliations

  1. Independent Pharmaceutical Consultant, Barcelona, Spain

    Antonio Guglietta

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Martin, G., Guglietta, A. (2015). Development of New Therapeutical Agents for Treatment of Insomnia and Other Sleeps Disorders. In: Guglietta, A. (eds) Drug Treatment of Sleep Disorders. Milestones in Drug Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-11514-6_4

Download citation

Publish with us

Policies and ethics

Search

Navigation